P. Brissot and O. Loréal, Iron metabolism and related genetic diseases: A cleared land, keeping mysteries, Journal of Hepatology, vol.64, issue.2
DOI : 10.1016/j.jhep.2015.11.009

URL : https://hal.archives-ouvertes.fr/hal-01231421

P. Brissot, E. Bardou-jacquet, A. Jouanolle, and O. Loreal, Iron disorders of genetic origin: a changing world, Trends in Molecular Medicine, vol.17, issue.12, pp.707-720, 2011.
DOI : 10.1016/j.molmed.2011.07.004

URL : https://hal.archives-ouvertes.fr/hal-00739428

P. Kanwar and K. Kowdley, Diagnosis and treatment of hereditary hemochromatosis: an update, Expert Review of Gastroenterology & Hepatology, vol.7, issue.6, pp.517-547, 2013.
DOI : 10.1586/17474124.2013.816114

J. Feder, A. Gnirke, and W. Thomas, A novel MHC class I???like gene is mutated in patients with hereditary haemochromatosis, Nature Genetics, vol.88, issue.4, pp.399-408, 1996.
DOI : 10.1016/0888-7543(95)80219-C

K. Allen, L. Gurrin, and C. Constantine, Hereditary Hemochromatosis, New England Journal of Medicine, vol.358, issue.3, pp.221-251, 2008.
DOI : 10.1056/NEJMoa073286

P. Cippa and P. Krayenbuehl, Hemochromatosis, New England Journal of Medicine, vol.369, issue.8, pp.785-791, 2013.
DOI : 10.1056/NEJMc1303066

O. Hermine, G. Dine, and V. Genty, Eighty percent of French sport winners in Olympic, World and Europeans competitions have mutations in the hemochromatosis HFE gene Non- HFE hemochromatosis: pathophysiological and diagnostic aspects, Biochimie. Bardou-Jacquet E Clin. Res. Hepatol. Gastroenterol, vol.8, issue.382, pp.143-54, 2014.

D. Wallace and N. Subramaniam, The global prevalence of HFE and non-HFE hemochromatosis estimated from analysis of next-generation sequencing dataPubmed ahead of print, Genet. Med. Lancet, vol.10, 2015.

S. Ribeiro, L. Belo, F. Reis, S. Porter, J. Garbowski et al., Iron therapy in chronic kidney disease: Recent changes, benefits and risks. Blood Rev The pathophysiology of transfusional iron overload, Hematol. Oncol, vol.12, 2015.

K. Musallam, M. Cappellini, J. Wood, and A. Taher, Iron overload in non-transfusion-dependent thalassemia: a clinical perspective, Blood Reviews, vol.26, issue.1, pp.16-25, 2012.
DOI : 10.1016/S0268-960X(12)70006-1

C. Pigeon, G. Ilyin, and B. Courselaud, A New Mouse Liver-specific Gene, Encoding a Protein Homologous to Human Antimicrobial Peptide Hepcidin, Is Overexpressed during Iron Overload, Journal of Biological Chemistry, vol.276, issue.11, pp.7811-7820, 2001.
DOI : 10.1074/jbc.M008923200

G. Nicolas, M. Bennoun, and I. Devaux, Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice, Proceedings of the National Academy of Sciences, vol.98, issue.15, pp.98-8780, 2001.
DOI : 10.1073/pnas.151179498

URL : https://hal.archives-ouvertes.fr/inserm-00331349

T. Ganz, Systemic Iron Homeostasis, Physiological Reviews, vol.93, issue.4, pp.1721-1762, 2013.
DOI : 10.1152/physrev.00008.2013

L. Kautz, G. Jung, E. Valore, S. Rivella, E. Nemeth et al., Identification of erythroferrone as an erythroid regulator of iron metabolism, Nature Genetics, vol.91, issue.7, pp.678-84, 2014.
DOI : 10.1002/hep.25615

L. Kautz, G. Jung, E. Nemeth, and T. Ganz, Erythroferrone contributes to recovery from anemia of inflammation, Blood, vol.124, issue.16, pp.2569-74, 2014.
DOI : 10.1182/blood-2014-06-584607

C. Hershko, G. Graham, G. Bates, E. Rachmilewitz, P. Brissot et al., Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity Non-transferrin bound iron: a key role in iron overload and iron toxicity, Br. J. Haematol. Biochim. Biophys. Acta, vol.40, issue.203, pp.255-63, 1978.

S. Kono, Aceruloplasminemia, Int. Rev. Neurobiol, vol.110, pp.125-51, 2013.
DOI : 10.1016/B978-0-12-410502-7.00007-7

D. Domenico, I. Ward, D. Di-patti, and M. , Ferroxidase activity is required for the stability of cell surface ferroportin in cells expressing GPI-ceruloplasmin, The EMBO Journal, vol.21, issue.12, pp.2823-312, 2007.
DOI : 10.1038/sj.emboj.7601735

B. Esposito, W. Breuer, P. Sirankapracha, P. Pootrakul, C. Hershko et al., Labile plasma iron in iron overload: redox activity and susceptibility to chelation, Blood, vol.102, issue.7, pp.2670-2677, 2003.
DOI : 10.1182/blood-2003-03-0807

L. Lan, C. Loreal, O. Cohen, and T. , Redox active plasma iron in C282Y/C282Y hemochromatosis, Blood, vol.105, issue.11, pp.4527-4558, 2005.
DOI : 10.1182/blood-2004-09-3468

Z. Cabantchik, W. Breuer, G. Zanninelli, and P. Cianciulli, LPI-labile plasma iron in iron overload, Best Practice & Research Clinical Haematology, vol.18, issue.2, pp.277-87, 2005.
DOI : 10.1016/j.beha.2004.10.003

Z. Cabantchik, Labile iron in cells and body fluids: physiology, pathology, and pharmacology, Frontiers in Pharmacology, vol.105, issue.e79870, 2014.
DOI : 10.1182/blood-2004-06-2226

D. Meynard, J. Babitt, H. Lin, L. Fletcher, and L. Powell, The liver: conductor of systemic iron balance, Blood, vol.123, issue.2, pp.168-76, 2003.
DOI : 10.1182/blood-2013-06-427757

M. Island, A. Jouanolle, and A. Mosser, A new mutation in the hepcidin promoter impairs its BMP response and contributes to a severe phenotype in HFE related hemochromatosis, Haematologica, vol.94, issue.5, pp.720-724, 2009.
DOI : 10.3324/haematol.2008.001784

URL : https://hal.archives-ouvertes.fr/inserm-00372237

C. Mclaren, M. Emond, and V. Subramaniam, Exome sequencing in HFE C282Y homozygous men with extreme phenotypes identifies a GNPAT variant associated with severe iron overload, Hepatology, p.2015, 1932.

L. Valenti, A. Fracanzani, and R. Rametta, Effect of the A736V TMPRSS6 polymorphism on the penetrance and clinical expression of hereditary hemochromatosis Evaluation of genome-wide loci of iron metabolism in hereditary hemochromatosis identifies PCSK7 as a host risk factor of liver cirrhosis, J.Hepatol. Hum. Mol. Genet, vol.57, issue.2314, pp.1319-1344, 2012.

Y. Deugnier, E. Bardou-jacquet, L. Lan, C. Brissot, and P. , Hyperferritin??mies non h??mochromatosiques, Gastroent??rologie Clinique et Biologique, vol.33, issue.4, pp.323-329, 2009.
DOI : 10.1016/j.gcb.2009.02.009

C. Larroche, Hemophagocytic lymphohistiocytosis in adults: Diagnosis and treatment, Joint Bone Spine, vol.79, issue.4, pp.356-61, 2012.
DOI : 10.1016/j.jbspin.2011.10.015

Y. Deugnier and F. Laine, Dysmetabolic iron overload syndrome: a systemic disease?], Presse Med, vol.436, pp.625-632, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01147025

K. Musallam and A. Taher, Iron-chelating therapy for transfusional iron overload, N. Engl. J

L. De-swart, J. Hendriks, and L. Van-der-vorm, Second International Round Robin for the Quantification of Serum Non-Transferrin-Bound Iron and Labile Plasma Iron in Patients with Iron- Overload Disorders. Haematologica Second round robin for plasma hepcidin methods: first steps toward harmonization, Am. J. Hematol, vol.87, issue.10, pp.977-83, 2012.

J. Wood, Estimating tissue iron burden: current status and future prospects, British Journal of Haematology, vol.147, issue.1, pp.15-28, 2015.
DOI : 10.1111/bjh.13374

J. Wood, Impact of iron assessment by MRI. Hematology / the Education Program of the Am Soc Hematol Educ Program, pp.443-50, 2011.

S. Pierre, T. Clark, P. Chua-anusorn, and W. , Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance, Blood, vol.105, issue.2, pp.855-61, 2005.
DOI : 10.1182/blood-2004-01-0177

Y. Gandon, D. Olivie, and D. Guyader, Non-invasive assessment of hepatic iron stores by MRI, The Lancet, vol.363, issue.9406, pp.357-62, 2004.
DOI : 10.1016/S0140-6736(04)15436-6

G. Porto, P. Brissot, and D. Swinkels, EMQN best practice guidelines for the molecular genetic diagnosis of hereditary hemochromatosis (HH), European Journal of Human Genetics, vol.47, issue.4, pp.83-90, 2015.
DOI : 10.1002/hep.24330

URL : https://hal.archives-ouvertes.fr/hal-01187326

Y. Deugnier and B. Turlin, Pathology of hepatic iron overload. Semin liver Dis, pp.260-71, 2011.

L. Legros, E. Bardou-jacquet, and M. Latournerie, Non-invasive assessment of liver fibrosis in C282Y homozygous HFE hemochromatosis, Liver International, vol.57, issue.6, pp.1731-1739, 2015.
DOI : 10.1111/liv.12762

URL : https://hal.archives-ouvertes.fr/hal-01134727

C. Mcdonald, L. Ostini, D. Wallace, A. Lyons, D. Crawford et al., Next-generation sequencing: Application of a novel platform to analyze atypical iron disorders, Journal of Hepatology, vol.63, issue.5, 1949.
DOI : 10.1016/j.jhep.2015.06.027

E. Angelucci, G. Brittenham, and C. Mclaren, Hepatic Iron Concentration and Total Body Iron Stores in Thalassemia Major, New England Journal of Medicine, vol.343, issue.5, pp.327-358, 2000.
DOI : 10.1056/NEJM200008033430503

T. Pascart, P. Richette, R. Flipo, P. Guggenbuhl, P. Brissot et al., Treatment of nongout joint deposition diseases: an update Haemochromatosis: The bone and the joint, Arthritis, vol.2014, pp.375202-53, 2014.

S. Sheth, Iron chelation, Current Opinion in Hematology, vol.21, issue.3, pp.179-85, 2014.
DOI : 10.1097/MOH.0000000000000031

A. Baksi, D. Pennell, Y. Deugnier, B. Turlin, and M. Ropert, Randomized controlled trials of iron chelators for the treatment of cardiac siderosis in thalassaemia major Improvement in liver pathology of patients with betathalassemia treated with deferasirox for at least 3 years HJV hemochromatosis, iron overload, and hypogonadism in a Brazilian man: treatment with phlebotomy and deferasirox, Front. Pharmacol. Gastroenterology. Acta Haematol, vol.5, issue.1244, pp.217-561202, 2010.

E. Fung and E. Nemeth, Manipulation of the hepcidin pathway for therapeutic purposes, Haematologica, vol.98, issue.11
DOI : 10.3324/haematol.2013.084624

E. Ramos, P. Ruchala, and J. Goodnough, Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis, Blood, vol.120, issue.18, pp.3829-3865, 2012.
DOI : 10.1182/blood-2012-07-440743

Y. Aydinok, A. Kattamis, and M. Cappellini, Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload, Blood, vol.125, issue.25, pp.3868-77, 2015.
DOI : 10.1182/blood-2014-07-586677

M. Elalfy, A. Adly, Y. Wali, S. Tony, A. Samir et al., Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients Reversal of hemochromatosis by apotransferrin in non-transfused and transfused Hbbth3/+ (heterozygous B1/B2 globin gene deletion) mice, Eur. J. Haematol. Haematologica, vol.62, issue.1005, pp.611-633, 2015.

P. Schmidt, T. Racie, M. Westerman, K. Fitzgerald, J. Butler et al., RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of ??-thalassemia intermedia, American Journal of Hematology, vol.122, issue.4, pp.310-313, 2015.
DOI : 10.1002/ajh.23934

S. Awadallah, Protein Antioxidants in Thalassemia, Adv. Clini.Chem, vol.60, pp.85-128, 2013.
DOI : 10.1016/B978-0-12-407681-5.00003-9

B. Moayedi, M. Gharagozloo, N. Esmaeil, M. Maracy, H. Hoorfar et al., A randomized double-blind, placebo-controlled study of therapeutic effects of silymarin in ??-thalassemia major patients receiving desferrioxamine, European Journal of Haematology, vol.2010, issue.3, pp.202-211, 2013.
DOI : 10.1111/ejh.12061

S. Das, J. Desaulniers, J. Dyck, Z. Kassiri, and G. Oudit, Resveratrol mediates therapeutic hepatic effects in acquired and genetic murine models of iron-overload. Liver Int, 2015.